CIBC Private Wealth Group LLC Sells 421,571 Shares of Pfizer Inc. $PFE

CIBC Private Wealth Group LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 46.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 483,199 shares of the biopharmaceutical company’s stock after selling 421,571 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Pfizer were worth $12,312,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PFE. State Street Corp raised its position in Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the second quarter valued at $2,270,157,000. Northern Trust Corp raised its holdings in shares of Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 1.9% in the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after buying an additional 897,786 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after buying an additional 1,135,457 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PFE shares. Royal Bank Of Canada initiated coverage on shares of Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. UBS Group initiated coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.14.

Pfizer Stock Performance

Shares of PFE stock opened at $27.40 on Friday. The stock has a market cap of $155.78 billion, a PE ratio of 20.14 and a beta of 0.47. The stock has a 50-day moving average of $26.65 and a 200-day moving average of $25.59. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 TALAPRO‑3 topline: the TALZENNA (talazoparib) + XTANDI (enzalutamide) combo met the study’s primary endpoint with a significant improvement in radiographic progression‑free survival for HRR‑mutated metastatic castration‑sensitive prostate cancer — a potential label expansion and commercial upside for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Atirmociclib Phase II success: a second‑line metastatic breast cancer study met its primary endpoint, strengthening Pfizer’s mid‑stage oncology pipeline and adding incremental clinical value that could support future partnerships or asset monetization. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst upgrades and bullish forecasts: recent analyst upgrades and an HSBC note highlighting strong upside have coincided with intraday buying and headline momentum, supporting the stock’s short‑term lift. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Positive Sentiment: Income/safety narrative: coverage framing Pfizer as a defensive, dividend‑paying option amid macro and oil volatility is attracting yield‑focused investors. That narrative helps support multiple expansion versus more cyclical sectors. Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.
• Neutral Sentiment: Pfizer vs Moderna sector comparison pieces highlight differing growth drivers (vaccines vs diversified pharma/oncology) but are more background for positioning than immediate stock movers. Pfizer vs Moderna: Which Pharma Stock Has More Upside?
• Neutral Sentiment: Early‑stage study updates: Pfizer advanced a PF‑07328948 liver study (Phase 1) while also closing one early melanoma program — incremental pipeline news that fine‑tunes expectations but doesn’t materially alter the company’s overall revenue base today. Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story
• Negative Sentiment: Program termination: Pfizer ended an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and highlights the usual R&D attrition risk that can temper optimism about pipeline breadth. Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not The Broader Pipeline

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.